IQVIA HoldingsNYSE: IQV

IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.

IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--As cancer incidence continues to rise, it's being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, “Global Oncology Trends 2024: Outlook to 2028.” “The global oncology ecosystem is operating near peak levels to address increasing challenges. New therapies for advanced cancers, including some of the most advanced novel science in the industr.

There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns from margin growth and capital productivity are driving exceptional free cash flow production.

Investors can use the Zacks Style Scores to quickly identify high-rated stocks that align with their investment style. Here's why you should make use of this tool.

IQVIA Holdings (IQV) reported quarterly earnings of $2.54 per share, exceeding the Zacks Consensus Estimate of $2.47 per share. This is higher than the earnings of $2.45 per share in the same quarter last year.

IQVIA's increase in revenues from specific segments leads to year-over-year growth in total revenue in the first quarter of 2024.

IQVIA Holdings' (IQV) revenues in the first quarter of 2024 are expected to have been boosted by the expansion of the Technology and Analytics, as well as Research and Development segments.

Going beyond the Wall Street estimates for IQVIA (IQV), examine key metrics to get a better understanding of the company's potential performance in the first quarter of 2024.